Asset profile
Lu AF28996
Small molecule
Evidence outlook · lead readout
NCT04291859 · Parkinson Disease
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT04291859: Everyone in this trial received Lu AF28996, with no placebo or other comparison group and no blinding, so on its own the trial cannot show whether any change seen was due to the drug. It was designed to find a tolerable dose and measure drug levels, not to test whether the drug improves Parkinson's symptoms. No results are posted yet.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2028 (1)
December 2028 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.